Printer Friendly
The Free Library
4,489,072 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

WYETH COMMENTS ON 3RD QUARTER AND FULL YEAR EARNINGS.


Wyeth (NYSE:WYE), Madison, N.J., has announced that pro forma diluted earnings per share for the 2005 third quarter is expected to be in the mid to upper seventy cent range, which exceeds the current First Call mean analyst estimate of $0.72 diluted earnings per share. Wyeth reaffirmed its 2005 full year pro forma diluted earnings per share guidance of $2.80 to $2.90 and noted that, if current business trends continue, full year earnings would more likely reach or even exceed the upper end of the range. These 2005 third quarter and full year earnings estimates are pro forma as they exclude restructuring charges resulting from the company's ongoing review of business processes and systems as well as the one- time impact from the repatriation of earnings from foreign subsidiaries under the American Jobs Creation Act, each of which will be described in the company's third quarter earnings release.

The company anticipates that year-over-year earnings growth in 2006 will be in the high single digit range. This estimated year-over-year earnings growth assumes 2005 pro forma earnings adjustment of approximately $0.17 per share to reflect the impact of expensing stock options. The company anticipates 2006 results will include the impact of accounting for stock options in accordance with the recently issued Statement of Financial Accounting Standards (SFAS) 123R, Share-Based Payment. This 2006 earnings growth estimate is considered pro forma as it excludes any potential restructuring charges resulting from the company's ongoing review of business processes and systems.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

For more information, visit http://www.wyeth.com or call 973/660-5340.

COPYRIGHT 2005 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Financial Reports
Date:Nov 1, 2005
Words:320
Previous Article:CELLERANT ADDS $9 MILLION TO SERIES B ROUND.
Next Article:LA JOLLA REPORTS $66 MILLION PRIVATE PLACEMENT.
Topics:

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles